ERRATUM

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Javier Cortés¹ · Hope S. Rugo² · Ahmad Awada³ · Chris Twelves⁴ · Edith A. Perez⁵ · Seock-Ah Im⁶ · Patricia Gómez-Pardo⁷ · Lee S. Schwartzberg⁸ · Veronique Diéras⁹ · Denise A. Yardley¹⁰ · David A. Potter¹¹ · Audrey Mailliez¹² · Alvaro Moreno-Aspitia¹ · Jin-Seok Ahn¹³ · Carol Zhao¹⁴ · Ute Hoch¹⁴ · Mary Tagliaferri¹⁴ · Alison L. Hannah¹⁵ · Joyce O'Shaughnessy¹⁶

Published online: 7 September 2017
© Springer Science+Business Media, LLC 2017

**Erratum to: Breast Cancer Res Treat (2017)
165(2):329–341
DOI 10.1007/s10549-017-4304-7**

The text in panel B of Fig. 1 (progression-free survival for patients with stable, treated brain metastases) was incorrectly labeled as mOS instead of mPFS. All other values and labels are correct. The corrected Figure 1 is given in this erratum.

The online version of the original article can be found under doi:[10.1007/s10549-017-4304-7](https://doi.org/10.1007/s10549-017-4304-7).

✉ Joyce O'Shaughnessy
joyce.oshaughnessy@usoncology.com

¹ Ramon y Cajal University Hospital, Madrid, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain

² University of California, San Francisco, CA, USA

³ Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

⁴ Leeds Institute of Cancer and Pathology and St James's University Hospital, Leeds, UK

⁵ Mayo Clinic, Jacksonville, FL, USA

⁶ Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

⁷ Vall d'Hebron Institute of Oncology, Barcelona, Spain

⁸ The West Clinic, Memphis, TN, USA

⁹ Institut Curie, Paris, France

¹⁰ Sarah Cannon Research Institute, Nashville, TN, USA

¹¹ Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

¹² Centre Oscar Lambret, Lille, France

¹³ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

¹⁴ Nektar Therapeutics, San Francisco, CA, USA

¹⁵ Consultant, Sebastopol, CA, USA

¹⁶ Texas Oncology-Baylor Charles A. Sammons Cancer Center/ U.S. Oncology, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA

Fig. 1 Kaplan–Meier estimates for **a** overall survival and **b** progression-free survival for patients with stable, treated brain metastases; and **c** overall survival for patients with radiologically detectable, but stable, brain lesions at study entry. *CI* confidence interval, *HR* hazard ratio, *mOS* median overall survival, *mPFS* median progression-free survival, *TPC* treatment of physician's choice